As my official term as ICIS President started in October of 2021 I’d like to offer a special thank you to Sarah Gaffen (President-Elect), and Joan Oefner and Elizabeth Gray, who manage the affairs of the society for the support they have already shown. Thank you also to the ICIS Council, and all of the dedicated individuals who serve on our committees for their ongoing service. Thank you to Simon Jones and his co-organizers for [READ MORE]

Society Business

  • At each Annual Scientific Meeting there shall be an Annual Business Meeting of the Membership of the Society, presided over by the President. Five percent of the Members shall constitute a quorum. This is the presentation of the 2021 Annual Business Meeting of the International Cytokine & Interferon Society which was postponed when the Annual meeting was not able to take place in Cardiff and pivoted to a Virtual Meeting. We invite members of the [READ MORE]

Cytokines 2022 Hybrid Joint Meeting with ILC4

Cytokines 2022 Hybrid Joint Meeting with ILC 4

Cytokines 2022 Hybrid: 10th Annual Meeting of the International Cytokine & Interferon Society (ICIS) to be held jointly with the 4th International Conference on Innate Lymphoid Cells (ILC4), September 20-23, 2022, at the Hilton Waikoloa Village, Big Island, Hawaii, USA, with synchronous Virtual Meeting Platform including live streamed and on-demand access to all sessions. Posters will be available both in-person (for those in Hawaii) AND as iPosters. [READ MORE]

New Member Mini-Bios

Jonathan C. Kagan, PhD

Jonathan C. Kagan, Ph.D.Marian R. Neutra, PhD Professor of PediatricsHarvard Medical SchoolDirector of Basic Research and Shwachman Chair in GastroenterologyBoston Children’s HospitalJon Kagan is a world leader in defining the molecular and cellular pathways by [READ MORE]

Juan Pedro Lapuente, PhD

Juan Pedro Lapuente, Ph.D.Hospital Universitario de FuenlabradaLivingCells LabFuenlabrada, Madrid, SpainDr. Juan Pedro Lapuente is a Medical Doctor from Zaragoza University, with several master’s degrees in cell and molecular biology and advanced therapies. He completed his [READ MORE]

Takashi Nishina, PhD

Takashi Nishina, Ph.D. Toho University Department of Biochemistry Ota-ku, Tokyo, Japan Twitter: @nishina_takashiTakashi Nishina is an Assistant Professor in the laboratory of Prof. Hiroyasu Nakano at Toho University School of Medicine, Japan. He completed his [READ MORE]

Fahar Merchant, PhD

Dr. Fahar MerchantPresident & CEOMedicenna TherapeuticsToronto, Canadawww.medicenna.com Dr. Fahar Merchant is a biotech veteran with 30 years of experience as a serial entrepreneur and co-founder, President and CEO of Medicenna Therapeutics Inc. Previously, he was [READ MORE]

Jan Pencik, PhD

Jan Pencik, PhDPostdoctoral FellowSalk Institute for Biological StudiesLa Jolla, United States2015 ICIS-Sidney & Joan Pestka Graduate Award WinnerJan Pencik is a NOMIS Center Postdoctoral Fellow at the Salk Institute for Biological Studies (La Jolla, US). [READ MORE]

Other Meetings of Interest

Clinical Trials

Clinical Trials

By Marta Catalfamo Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19 (STRIKESARS)Principal Investigator: Javier J Zulueta, MD. Clinica Universidad de Navarra, Universidad de Navarra. Pamplona, Navarra, Spain, 31008Contact: Gabriel Canel, Phone: +34948255400ClinicalTrials.gov Identifier: [READ MORE]

Special Article of Interest

  • Dragana Lj. Jankovic, Ph.D.Credit: NIAIDDr. Dragana JankovicNIAID, NIHThe current model of CD4+ T helper subsets is founded on both differentially expressed cytokines and the distinct functions mediated by these cytokines. It comprises the initially identified Th1 and Th2 effector cells as well as Th17 and Tfh lymphocytes (depicted with big circles). The complexity of Th [READ MORE]

Signals+ PDF

  • Signals+ Newsletter in PDF format for viewing, downloading and/or printing. Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)

Stay connected & please share